Related Experiment Video
Updated: Jul 16, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
An updated patent review of stimulator of interferon genes agonists (2021 - present)
Guo-Feng Xin1,2, Nan-Nan Chen1,2, Lin-Lin Li1,2
1State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Introduction:
Stimulator of Interferon Genes (STING) is an innate immune sensor. Activation of STING triggers a downstream response that results in the expression of proinflammatory cytokines (TNF-α, IL-1β) via nuclear factor kappa-B (NF-κB) or the expression of type I interferons (IFNs) via an interferon regulatory factor 3 (IRF3). IFNs can eventually result in promotion of the adaptive immune response including activation of tumor-specific CD8+ T cells to abolish the tumor. Consequently, activation of STING has been considered as a potential strategy for cancer treatment.
Areas Covered:
This article provides an overview on structures and pharmacological data of CDN-like and non-nucleotide STING agonists acting as anticancer agents (January 2021 to October 2023) from a medicinal chemistry perspective. The data in this review come from EPO, WIPO, RCSB PDB, CDDI.
Expert Opinion:
In recent years, several structurally diverse STING agonists have been identified. As an immune enhancer, they are used in the treatment of tumors, which has received extensive attention from scientific community and pharmaceutical companies. Despite the multiple challenges that have appeared, STING agonists may offer opportunities for immunotherapy.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Modified-Release Drug Delivery Systems: Stimuli-Activated
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly

